An interventional study of High intensity training in Attention Deficit Disorder With Hyperactivity (ADHD), sponsored by Solli Distriktspsykiatriske Senter. Enrolling by invitation at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.
Sponsored by Solli Distriktspsykiatriske Senter · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Attention Deficit Disorder with Hyperactivity with a site in Norway — 4 open to participants now, 7 under way, none of them phase 3. Attention Deficit Disorder with Hyperactivity · Norway.
Among the 30 studies in Attention Deficit Disorder with Hyperactivity with a site in Norway, this one is the 23rd largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2026, is one of 17 with no phase, and was the 30th registered.
1,821 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 297 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →4 of the 30 studies in Attention Deficit Disorder with Hyperactivity with a site in Norway are open now. Recruiting first, the newest first:
Sorlandet Hospital HF · Sites in Norway
Ages 5–18 · Healthy volunteers
St. Olavs Hospital · Sites in Norway
Ages 18–65
Royal Devon and Exeter NHS Foundation Trust · Sites in Norway, United States, Italy and 1 more country
Ages 2–50
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 200 Attention Deficit Disorder with Hyperactivity studies recruiting now, 26 (13%) set no upper age limit and 169 (85%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 72 across 1,439 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 100 across the 25 interventional studies, 187 across the 5 observational. Of the 20 that completed or were terminated, 5 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 30 have an industry lead sponsor. The 10 most frequent:
Solli Distriktspsykiatriske Senter is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Solli Distriktspsykiatriske Senter has 1 study filed under Attention Deficit Disorder with Hyperactivity — fewer than ten, so there is no comparison to draw.
3 of the studies in Attention Deficit Disorder with Hyperactivity with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06284655St. Olavs HospitalThe Effect of a Brief Educational Intervention for Adults With ADHD | 2027-01 |
| NCT07675538Solli Distriktspsykiatriske SenterHigh Intensity Training for Adults With ADHD in Specialised Mental Health Care | 2027-06-01 |
| NCT06299189Haukeland University HospitalA Therapist Guided Internet-delivered Treatment for Adults With ADHD (Attention Deficit / Hyperactivity Disorder) - an Open Effectiveness Trial in Routine Care | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 30 studies in Attention Deficit Disorder with Hyperactivity with a site in Norway, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Attention-Deficit/Hyperactivity Disorder (ADHD) is a lifelong neurodevelopmental disorder characterised by persistent symptoms of inattention, hyperactivity, and impulsivity. According to the DSM-5, these symptoms must be present for at least six months, have an onset in childhood, and result in significant impairment in multiple life domains. Although ADHD may be limited to childhood in some cases, most individuals continue to have symptoms and impairments in varying degrees in adult life. The prevalence of persistent ADHD among adults is estimated to be approximately 2.58%, depending on diagnostic criteria and sample selection. The increasing awareness of ADHD has led to a marked increase in referrals to mental health services, which places greater demands on the development of effective and accessible treatment options for this group.
Pharmacological treatment, particularly the use of stimulants, is a common intervention for adults with ADHD and has been shown to be effective for many. However, there are also side effects associated with drug treatment, and there is a need for more evidence-based non-drug alternatives. In addition, discontinuation of medication is common in ADHD treatment. Psychological interventions include psychoeducation and cognitive behaviour therapy, as well as more specialised approaches based on Dialectical Behaviour Therapy and Goal Management Training, which aim to improve executive functions. Whilst pharmacotherapy and psychotherapeutic interventions help some people with ADHD, not all people experience favourable outcomes, which calls for alternative treatment approaches. Interventions targeting the core symptoms of ADHD, executive functions, and behaviour are particularly relevant to treatment provision.
One approach to improving executive functioning that has received increasing attention is physical exercise. Studies have shown that physical activity can have a positive effect on cognitive function, executive control, and behaviour in children and adolescents with ADHD. Physical exercise may also be applied as treatment for comorbid factors common in ADHD, such as mood disorders and multiple long-term physical conditions. Despite increasing interest in physical activity as a treatment modality, research on physical exercise for adults with ADHD is still limited. The findings from studies on younger age groups point to the potential for similar effects in adults, but more research is needed to examine the effects of physical exercise as a targeted intervention in the adult population with ADHD.
Among the different types of physical activity, high-intensity interval training (HIIT) has gained promise for mental health. Due to its rapid, alternating, and fast-paced style, it could prove useful for those with ADHD. However, research on high-intensity interval training interventions (HIIT) in this population is scarce. To address these unanswered questions, this project will conduct a feasibility trial for a randomised controlled trial (RCT) to assess the feasibility and acceptability of HIIT among people with ADHD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Fourteen weeks of high intensity strenght and endurance training after a protocol.
Behavioral: High intensity training
14 weeks of high intensity training of strenght and endurace.
Feasibility of the intervention: Recruitment rate
Recruitment rate: Proportion of eligible participants who agree to participate in the study ((Number of participants recruited/Number of eligible participants) x 100). Aim: \>50%.
Time frame: through study completion, an average of 1 year
Feasibility measure: Retention rate
Retention rate: Proportion of participants who remain in the study until completion ((Number of participants completing the study/Number of participants enrolled) x 100). Aim: \>80%.
Time frame: through study completion, an average of 1 year
Feasibility measure: Dropout rate
Dropout rate: How many participants dropped out after inclusion. Registration of reasons of dropout.
Time frame: through study completion, an average of 1 year
Feasibility measure: Compliance
Compliance: How many sessions each participant attended. Registration of reasons of sessions not attended.
Time frame: through study completion, an average of 1 year
Feasibility measure: Adherence to protocol
Adherence to protocol: How many elements in the physical exercise program were conducted in each session. Physical exercise diary for registration of load and intensity of strength- and endurance training, respectively. Aim: \>80%. Also, registration of adherence to the total test protocol.
Time frame: through study completion, an average of 1 year
In depth interview
Participants will be invited to an in-depth interview lasting approx. 45 minutes, after the treatment intervention. The aim is to explore experiences with physical exercise in relation to core symptoms of ADHD. A semi-structured interview protocol with open questions and additional probes is used to promote exploratory dialogue on the participants experience with participation. All interviews will be audio recorded and transcribed verbatim. By comparing the individual accounts, we want to identify both patterns of commonalities and differences in participants' experiences, providing important descriptions of patient experiences that may contribute to detect challenges with the intervention that can be utilised for further development and implementation.
Time frame: Participants are inviteted within two weeks after ending their participation
General Ability - WAIS-IV
Six sub tests from the general ability test Wecshler Adult Intelligence Scale will be used to assess General Ability Index, Verbal Comprehension Index and Perceptual Reasoning Index. The six subtests are: Block Design, Similarities, Matrix Reasoning, Vocabulary, Digit Span and Coding.
Time frame: Within two weeks before initating intervention.
The Adult ADHD Self-Report Scale
The Adult ADHD Self-Report Scale (ASRS) is a patient-reported outcome measure assessing the frequency and severity of adult ADHD symptoms. Items are rated on a 5-point Likert scale (0-4), with higher total scores reflecting greater ADHD symptom severity. Lower scores reflect fewer self-reported ADHD symptoms.
Time frame: Within two weeks before initating intervention. Within two weeks after ending intervention.
The Working Memory Questionnaire
The Working Memory Questionnaire (WMQ) is a patient-reported outcome measure designed to assess everyday difficulties related to working memory functioning. It evaluates the frequency of memory-related problems experienced in daily life, including difficulties with remembering information, maintaining attention, following instructions, and managing cognitive tasks. The WMQ consists of items rated on a Likert-type scale, where participants indicate how often they experience specific working memory difficulties. A total score is calculated by summing item responses. Higher scores indicate greater perceived working memory difficulties and a higher level of impairment in everyday cognitive functioning. Lower scores indicate fewer reported working memory problems and better perceived working memory functioning. The total WMQ score is calculated by summing responses across items (with item scoring depen
Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.
The Generalized Anxiety Disorder-7
The Generalized Anxiety Disorder-7 (GAD-7) is a patient-reported outcome measure assessing anxiety symptom severity. Items are scored from 0-3 based on symptom frequency over the previous two weeks, producing a total score from 0-21. Higher scores indicate greater anxiety symptom severity, while lower scores indicate fewer anxiety symptoms
Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.
The Patient Health Questionnaire-9
The Patient Health Questionnaire-9 (PHQ-9) is a patient-reported outcome measure assessing depressive symptom severity. Items are scored from 0-3 based on symptom frequency over the previous two weeks, producing a total score from 0-27. Higher scores indicate greater depressive symptom severity, while lower scores indicate fewer depressive symptoms.
Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.
The Bergen Insomnia Scale
The Bergen Insomnia Scale (BIS) is a patient-reported outcome measure assessing insomnia symptoms and sleep-related impairment. Six items are rated from 0-7 according to symptom frequency over the previous month, producing a total score from 0-42. Higher scores indicate greater insomnia symptom severity, while lower scores indicate fewer insomnia symptoms.
Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.
The International Physical Activity Questionnaire
The International Physical Activity Questionnaire (IPAQ) is a patient-reported outcome measure assessing physical activity and sedentary behavior. It measures frequency and duration of walking, moderate-intensity, and vigorous-intensity activities over a specified recall period. Scores are calculated as MET-minutes/week, with higher scores indicating greater physical activity and lower scores indicating less physical activity.
Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.
The Work and Social Adjustment Scale
The Work and Social Adjustment Scale (WSAS) is a patient-reported outcome measure assessing functional impairment associated with a health condition. Five items are rated from 0-8, producing a total score from 0-40. Higher scores indicate greater impairment in work, social, and daily functioning, while lower scores indicate better functioning.
Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.
The Adult ADHD Quality of Life
The Adult ADHD Quality of Life (AAQoL) is a validated self-report questionnaire designed to assess health-related quality of life in adults with attention-deficit/hyperactivity disorder (ADHD). The instrument evaluates the impact of ADHD symptoms on daily functioning and well-being across multiple domains, including life productivity, psychological health, relationships, and outlook. The AAQoL consists of 29 items, each rated on a Likert-type scale reflecting the frequency or severity of difficulties experienced over a specified recall period. Item responses are combined and transformed into domain scores and an overall total score. Item responses are aggregated and converted to standardized scores ranging from \*\*0 to 100\*\* for the total scale and each domain. Higher scores indicate better health-related quality of life, while lower scores indicate poorer quality of life and greater ADHD-related f
Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.
Credibility/Expectancy Questionnaire
The Credibility/Expectancy Questionnaire (CEQ) is a patient-reported measure assessing perceived treatment credibility and expectancy for improvement. It consists of 5 items where patients rate themselves on a likert scale from 0-10. It produces a total scores, with higher scores indicating greater perceived credibility and stronger expectations of treatment benefit.
Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.
The Negative Effects Questionnaire - Short Form
The Negative Effects Questionnaire - Short Form (NEQ-S) is a patient-reported outcome measure assessing perceived negative or unwanted effects of an intervention. Higher scores indicate a greater number and/or severity of self-reported adverse effects.
Time frame: Within two weeks after completion of the last session.
The Wechsler Memory Scale - Third Edition
The Wechsler Memory Scale - Third Edition (WMS-III) Spatial Memory subtest is a clinician-administered measure of visuospatial memory. Standardized age-adjusted scores are derived, with higher scores indicating better spatial memory performance and lower scores indicating poorer spatial memory.
Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.
D-KEFS Trail Making Test
The D-KEFS Trail Making Test is a clinician-administered measure of executive function assessing visual scanning, processing speed, and cognitive flexibility. Performance is measured by time to completion and standardized scaled scores, with higher scores (and faster completion times) indicating better executive functioning."
Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.
D-KEFS Color-Word Interference Test
The D-KEFS Color-Word Interference Test is a clinician-administered measure of executive function assessing response inhibition and cognitive flexibility. Performance is measured by time to completion and standardized scaled scores, with higher scores (and faster completion times) indicating better executive functioning.
Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.
Maximal strenght
Maximal strength is assessed using the one-repetition maximum (1RM) test for lower-body and upper-body strength. In this study, maximal lower-body strength is assessed using a leg strength exercise (e.g., leg press or squat depending on protocol), and upper-body strength is assessed using the bench press. The primary outcome is the maximal load lifted successfully for one repetition, recorded in kilograms (kg). Separate 1RM values are obtained for leg strength and bench press. Higher scores: Indicate greater maximal muscular strength and neuromuscular performance in the tested muscle groups. Lower score
Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.
Maximal oxygen uptake
Maximal oxygen uptake (VO₂max) is an estimate of the maximum rate at which oxygen can be utilized during intense aerobic exercise and is a key indicator of cardiorespiratory fitness. In this study, VO₂max is estimated using the Myworkout GO mobile application (Helgerud et al., 2022), which derives VO₂max from performance data collected during a standardized treadmill-based interval protocol (4×4 endurance session). The estimation is based on recorded treadmill speed and incline during the exercise session, which are used to model aerobic capacity according to validated predictive algorithms. VO₂max is reported as an estimated continuous variable in milliliters of oxygen per kilogram of body weight per minute (mL·kg-¹·min-¹). Higher values indicate greater aerobic capacity and cardiorespiratory fitness, while lower values indicate reduced aerobic fitness.
Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.
Plan to share: No — This has not been applied for to the ethical Committee.
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Jun 2027, 16 months after the start.
Of 480 non-industry interventional studies with no phase under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 16 months is below that.
Counting every sponsor, half of 511 studies reached it within 23 months; a quarter within 11 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Attention Deficit Disorder with Hyperactivity →
Solli Distriktspsykiatriske Senter